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(SD = 0.15). CONCLUSION: Results obtained thus far suggest
that the HRQL of CLL patients in remission is high. Patients
utilize the additional categories provided with a 5-level instru-
ment. However, in this case the labelled levels still attracted the
greatest percentage of answers, which may be a function of the
design of the questionnaire.
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OBJECTIVES: Progression-free survival (PFS) has not been vali-
dated as a surrogate endpoint for overall survival (OS) for
anthracycline-based (A) or taxane-based (T) chemotherapy in
metastatic breast cancer (MBC). Using a meta-analytic trial-level
approach, we evaluated the relationship between PFS and OS.
METHODS: A literature review identiﬁed all randomized, con-
trolled A and T trials for MBC. Progression-based endpoints
were classiﬁed by prospective deﬁnitions. Treatment effects were
derived as hazard ratios (HR) for PFS (HRPFS) and OS (HROS)
from trial data (constant rate assumption). The kappa statistic
assessed overall agreement. HROS was predicted from trial HRPFS
using ﬁxed effects models that were internally validated. Sensi-
tivity and subgroup analyses were performed for the constant
rate assumption, PFS deﬁnition, year of last patient recruitment,
and line of treatment. RESULTS: Inclusion criteria were met by
15 A and 16 T trials, allowing 17 A (n = 4155) and 17 T
(n = 5509) comparisons. The direction of HROS and HRPFS
agreed in 25% (A) to 50% (T) (negative) and in 62.5% (A) to
50% (T) (positive) (kappa = 0.71, p = 0.0029 (A); kappa = 0.75,
p = 0.0028 (T)). HRPFS was a signiﬁcant predictor of HROS for A
(p = 0.0019) and T (p = 0.012) in the ﬁxed effects models, with
explained variance (R2) of 0.35 (T) and 0.49 (A). Cross valida-
tion showed that 97% of the 95% prediction intervals crossed
the equivalence line. The direction of predicted HROS agreed with
observed HROS in 82% (A) and 76% (T). Results were robust in
sensitivity and subgroup analyses. CONCLUSION: This analysis
suggests the treatment effect on PFS is signiﬁcantly associated
with the treatment effect on OS. However, prediction of OS
based on PFS is surrounded with uncertainty: Half (A) to one
third (T) of the OS treatment effect variance is explained by the
PFS treatment effect variance. Using limited data, sensitivity and
subgroup analysis did not explain result heterogeneity.
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OBJECTIVES: To evaluate if quality-adjusted survival for tem-
sirolimus (TEMSR) met criteria for minimal clinically important
difference (MCID) in a randomized, outpatient study of ﬁrst-line
treatment of patients with poor-prognosis, advanced renal cell
carcinoma (RCC). In this study TEMSR (25 mg IV once-weekly)
was associated with median 10.9 months overall survival
(OS) compared with median 7.3 months OS for interferon
(IFN) (up to 18 MU subcutaneously thrice weekly (p = 0.008).
METHODS: OS was partitioned into 3 distinct periods: a) time
in serious toxicity (aggregated time in grade 3 or 4 adverse events
(AEs); b) time in progression (based on tumor response assess-
ment); and c) time without symptoms of progression or toxicity
(TWiST). Based on patient-reported responses to the EuroQol
(EQ-5D) at representative time points during each period,
Q-TWiST was estimated as the measure of quality-adjusted sur-
vival. Treatment group differences in Q-TWiST were evaluated in
terms of restricted means, with patient follow-up truncated at the
median of 17.9 months. Variance and covariance were estimated
using bootstrap methods. Following published literature, the
clinical importance of the TEMSR-IFN difference in Q-TWIST
was the percentage obtained when this difference was divided by
mean OS for IFN (the control group). RESULTS: All 626 ran-
domized patients were included in computation of health state
durations. Response rates for the EQ-5D were 87% (260/300)
during progression, 40% (230/570) during toxicity, and 99%
(278/279) during TWiST. Patients in the TEMSR group had 1.3
months greater Q-TWiST than those in the IFN group
(TEMSR = 7.0 months vs. IFN = 5.7 months; p = 0.0015). The
MCID was 14.8% (1.3 months divided by 8.8 months [IFN
mean OS]), which is within the published range of 10–15% for
MCID in cancer trials. CONCLUSION: Patients with advanced
RCC receiving TEMSR met criteria for clinically important
improvement in quality-adjusted survival.
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OBJECTIVES: The MABEL study is an open label, uncontrolled,
multi-centre, study of cetuximab in combination with irinotecan
in patients with EGFR expressing mCRC and having progressed
on a recent irinotecan-based treatment regimen. A study objec-
tive was to assess quality of life (QoL). This abstract will report
on ﬁndings on 126 patients from 28 UK sites. METHODS: QoL
was assessed using the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) and the EQ-5D. The QLQ-C30 questionnaire com-
prises 30 items, organised into global health status, functionality,
symptomatology and single items. The EQ-5D questionnaire
consists of the EQ-5D descriptive system and the Visual Ana-
logue Scale (VAS). QoL changes were assessed on patients with a
baseline and at least one post-baseline assessment. RESULTS: At
the 6 week assessment, 88 [69.8%] patients completed at least
one QoL item, with 71 [56.3%] patients at 12 weeks, and 41
[32.5%] patients at the end of the study visit. Given the loss of
two thirds of data by the end of study, the following results will
assess data over a 12 week period. Between baseline and 12
weeks the EORTC QLQ-C30 global health score increased
slightly from 65.3–68.9. Symptomatic scales reported a similar
trend with the exception of diarrhoea and ﬁnancial difﬁculties
single items. The EQ-5D index and VAS also reported a trend for
a slight improvement between baseline (0.73 and 0.90 respec-
tively) and 12 weeks (0.77 and 0.93 respectively.) CONCLU-
SION: It is important to consider these results in context of
patient prognosis and treatment administered. The data suggests
A342 Abstracts
that patient QoL is maintained following the introduction of
cetuximab plus irinotecan over 12 weeks. However, we must be
mindful of the population of patients assessed/ followed up, the
lack of comparator information and the issues of open label
studies.
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OBJECTIVES: The purpose of this study was to assign utilities to
the three different severity grades of hand-foot-syndrome (HFS)
which is a dose and therapy limiting toxicity in cancer patients
undergoing treatment with e.g. capecitabine, docetaxel, sunitinib
and sorafenib. HFS can develop from mild skin reactions at
hands and feet (grade 1) to major skin reactions with bleeding,
ulceration and severe pain (grade 3). METHODS: In a survey
conducted in a German community pharmacy, randomly chosen
subjects were introduced to the symptoms of HFS using cards
explaining the different HFS grades by pictures of hands and feet,
a clinical deﬁnition and citations of patients. Participants were
asked to imagine suffering from each HFS grade for the next 10
years followed by death. Then they valuated the different grades
using the time-trade-off-method (TTO) and the visual analogue
scale (VAS). RESULTS: Fifty-three participants (30 female =
56.6%, 23 male = 43.4%) valuated the different HFS grades.
Their mean age was 50.8 years (median: 49.0, SD: 18.5, range:
18–86 years). The following mean utilities were assessed using
the TTO: grade 1 = 0.97 (median: 1.00, SD: 0.08), grade
2 = 0.72 (median: 0.80, SD: 0.23) and grade 3 = 0.34 (median:
0.30, SD: 0.22). The VAS resulted in the following mean utilities:
grade 1 = 0.70 (median: 0.70, SD 0.14), grade 2 = 0.37 (median:
0.40, SD: 0.13) and grade 3 = 0.09 (median: 0.10, SD: 0.08). All
differences among the severity grades were statistically signiﬁcant
(p < 0.001). CONCLUSION: The adults questioned see a signiﬁ-
cant impact of the adverse drug reaction HFS on the health status
of patients. Therefore HFS deserves awareness and respect by
health care professionals and requires a high level of patient
information. Furthermore scientists should be encouraged to
conduct more studies concerning prevention and management
of HFS.
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OBJECTIVES: The EQ-5D visual analog scale (VAS) is a patient-
reported rating of overall health that is often reported in clinical
studies. However, few studies are available to guide in the inter-
pretation of meaningful differences in VAS scores. The objective
of this study was to estimate meaningful differences in EQ-5D
VAS scores in cancer, particularly in lung cancer. METHODS:
Secondary data analysis was conducted on a cross sectional study
of 534 cancer patients, including 50 lung cancer patients, who
completed EQ-5D VAS (scaled from 0 (worst imaginable health)
to 100 (best imaginable health)). Anchor-based and distribution
based approaches were used to estimate important differences for
VAS scores. Cancer patients were grouped into clinically mean-
ingful categories anchored by: 1) Eastern Cooperative Oncology
Group performance status (PS), and 2) FACT-G total score-based
quintiles. These anchors were conservative partitions likely to
exceed the true minimum important difference (MID).
Distribution-based criteria applied to each subgroup included 1/2
standard deviation (SD) and the standard error of the measure
(SEM). RESULTS: Estimates of MID for VAS scores based on PS
categories ranged from 8 (average mean difference across catego-
ries) to 11 (SEM) for all cancer patients, and from 8 (0.5 SD) to
12 (average mean difference across PS categories) for lung cancer
patients. Using FACT-G score quintiles, MIDs were the same for
both the overall cancer groups and the lung cancer subgroup
where the average mean difference between quintiles was 7, SEM
was 10 and 1/2 SD was 9. CONCLUSION: The range of esti-
mates representing important differences in EQ-5D VAS scores
was similar between all cancers and lung cancer (7 to 12), with
the lower bounds of MID estimates closer to minimal important
differences, i.e. 7–8. These estimates can help to inform interpre-
tation of EQ-5D VAS scores, particularly in studies of cancer.
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OBJECTIVES: Cancer-related fatigue (CRF) is a frequently
reported complaint in cancer patients and survivors. The Perform
Questionnaire (PQ) is a recently validated scale to assess percep-
tions and beliefs about CRF. This study aims to determine how
sensitive to change is the PQ as well as to compare it with the
sensitivity of the FACT-F. METHODS: An observational and
longitudinal multi-centre study was carried out on a sample of
cancer patients with a moderate level of CRF. PQ and FACT-F
were administered at inclusion and 3 months later, as well as
sociodemographics and key clinical indicators. Patient improve-
ment or worsening related to CRF was assessed by means of a
health status item (HSI) self-administered at the second visit on a
Likert-type ordinal scale with 13 response options. RESULTS:
Baseline patient characteristics (n = 437) were: 60.5% women,
mean age 59.1 years, an average of 2.21 years since diagnosis,
33.6% breast cancer, 54.7% with metastasis, Karnofsky mean
score 80.9, and 29.1% with anaemia. Of the 350 patients who
assessed their change with HSI: 208 (59.4%) reported improve-
ment (‘slightly’ to ‘greatly’), 84 (24%) reported worsening
(‘slightly’ to ‘greatly’), and 58 (16.6%) reported no signiﬁcant
change. The overall PQ score showed a better sensitivity to
clinical deterioration (effect 1.04) than to the improvement
(effect size = 0.57), similar to the magnitude of the effect sizes
obtained with FACT-F (0.91 for deterioration; 0.53 for improve-
ment). The effect sizes of PQ dimensions were also higher for the
patients reporting worsening (ranging from 0.92 to 1.06) than
for those reporting improvements (0.51 to 0.59). CONCLU-
SION: The score of PQ has demonstrated a good level of sensi-
tivity both in patients reporting improvement and in patients
reporting deterioration of health status, in a similar magnitude
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